JP2022537914A - アポリポタンパク質ｅ断片 - Google Patents

アポリポタンパク質ｅ断片 Download PDF

Info

Publication number
JP2022537914A
JP2022537914A JP2021572057A JP2021572057A JP2022537914A JP 2022537914 A JP2022537914 A JP 2022537914A JP 2021572057 A JP2021572057 A JP 2021572057A JP 2021572057 A JP2021572057 A JP 2021572057A JP 2022537914 A JP2022537914 A JP 2022537914A
Authority
JP
Japan
Prior art keywords
apoe
fragment
apolipoprotein
seq
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537914A5 (cg-RX-API-DMAC10.html
Inventor
博昭 萩原
勘太 堀江
邦彦 金津
康晴 石原
康彰 後藤
徹 隠岐
將史 壷井
シャーロット サーリン，
マリア エリクソン，
クリステル メラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2022537914A publication Critical patent/JP2022537914A/ja
Publication of JP2022537914A5 publication Critical patent/JP2022537914A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
JP2021572057A 2019-06-28 2020-06-25 アポリポタンパク質ｅ断片 Pending JP2022537914A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183411.8 2019-06-28
EP19183411.8A EP3757121A1 (en) 2019-06-28 2019-06-28 Apolipoprotein e fragments
PCT/EP2020/067858 WO2020260471A1 (en) 2019-06-28 2020-06-25 Apolipoprotein e fragments

Publications (2)

Publication Number Publication Date
JP2022537914A true JP2022537914A (ja) 2022-08-31
JP2022537914A5 JP2022537914A5 (cg-RX-API-DMAC10.html) 2023-06-05

Family

ID=67225988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572057A Pending JP2022537914A (ja) 2019-06-28 2020-06-25 アポリポタンパク質ｅ断片

Country Status (5)

Country Link
US (1) US20220251171A1 (cg-RX-API-DMAC10.html)
EP (2) EP3757121A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022537914A (cg-RX-API-DMAC10.html)
CN (1) CN114008072A (cg-RX-API-DMAC10.html)
WO (1) WO2020260471A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127347A1 (en) * 2020-10-26 2022-04-28 The Regents Of The University Of California Inhibition of Tau Propagation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051998A2 (en) * 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"preapolipoprotein E[Homo sapiens]", NCBI PROTEIN DB [ONLINE], JPN6024014316, 21 October 2002 (2002-10-21), ISSN: 0005512258 *
JOURNAL OF NEUROCHEMISTRY, vol. 72, JPN6024014315, 1999, pages 230 - 237, ISSN: 0005512257 *

Also Published As

Publication number Publication date
US20220251171A1 (en) 2022-08-11
EP3757121A1 (en) 2020-12-30
EP3990482A1 (en) 2022-05-04
WO2020260471A1 (en) 2020-12-30
CN114008072A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
Wiltfang et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
Handattu et al. In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathology
Wang et al. Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
Hartlage-Rübsamen et al. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Waragai et al. Importance of adiponectin activity in the pathogenesis of Alzheimer's disease
US20150337030A1 (en) Methods to treat alzheimer's disease using apoe inhibitors
JP2023081919A (ja) チューブリンカルボキシペプチダーゼ関連疾患を処置するための方法及び医薬組成物
Mukherjee et al. Citrullination of amyloid-β peptides in Alzheimer’s disease
JP7654126B2 (ja) アルツハイマー病の判定薬および判定方法
Tate et al. Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice
Kasri et al. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial alzheimer’s disease with app dup and down syndrome
Cho et al. Peroxiredoxin 5 regulates osteogenic differentiation through interaction with hnRNPK during bone regeneration
US20220251171A1 (en) Apolipoprotein e fragments
Ju et al. Distinct properties of murine α5 γ‐aminobutyric acid type a receptors revealed by biochemical fractionation and mass spectroscopy
US20220034913A1 (en) Methods and compostions of detecting and treating neurodegenerative disorders
EP2817632B1 (en) New dual biomarker of neurodegeneration and of neuroregeneration
AU2016235685B2 (en) Method of diagnosis or treatment of neurological disorders with p75ECD and/or p75
EP4071165A1 (en) A new non-aggregative splicing isoform of human tau is decreased in alzheimer s disease
KR101240136B1 (ko) 아스피린 과민성 천식 진단용 바이오마커
JP4800387B2 (ja) ＧＣＰＩＩ（Ｇｌｕｔａｍａｔｅｃａｒｂｏｘｙｐｅｐｔｉｄａｓｅ−ＩＩ）を有効成分として含むβアミロイドの脳内蓄積予防及び治療用薬学的組成物と治療剤スクリーニング用組成物及びそれを使用したスクリーニング方法
KR100896237B1 (ko) 퇴행성 신경질환의 치료를 위한 카텝신 ｄ의 신규한 용도
Sutter et al. Astrocytic TIMP-1 regulates production of Anastellin, a novel inhibitor of oligodendrocyte differentiation and FTY720 responses
Alhadidy Uncommonly studied post-translational modifications as potential regulators of tau function and pathobiology
RU2797200C1 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)
RU2812207C2 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211206

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250722